Phase 4
Completed N=220
Corticosteroids for Acute Migraine in the Emergency Department
Source: ClinicalTrials.gov NCT02847494 ↗Enrolled (actual)
220
Serious AEs
0.0%
Results posted
Jan 2019
Primary outcomePrimary: Headache Days as Self-reported by Participants — 3.0; 3.3 days
◆ Published Evidence
Established
▲ Trending
20citations · ~3 / year
A Randomized Trial of a Long-Acting Depot Corticosteroid Versus Dexamethasone to Prevent Headache Recurrence Among Patients With Acute Migraine Who Are Discharged From an Emergency Department.
Summary
This is an emergency department based randomized trial in which we compare two different treatment for migraine headache. The goal is to decrease the number of headache days during the week after ED discharge.
Linked Publications
-
A Randomized Trial of a Long-Acting Depot Corticosteroid Versus Dexamethasone to Prevent Headache Recurrence Among Patients With Acute Migraine Who Are Discharged From an Emergency Department.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Headache Days as Self-reported by Participants |
3.0; 3.3 | — |
| SECONDARY Number of Participants With Sustained Headache Freedom |
10; 6 | — |
| SECONDARY Medication Preference as Assessed by Self-report |
76; 75 | — |
Eligibility Criteria
Inclusion Criteria
- Migraine without aura criteria (International Classification of Headache Disorders 3B )
- Headache rated as moderate or severe in intensity
Exclusion Criteria
- Concern for secondary cause of headache
- Contra-indications to investigational medications
Data sourced from ClinicalTrials.gov (NCT02847494) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.